Description
GLP-1 (C/S) is a defined two-component research blend combining Cagrilintide and Semaglutide in equal proportions. The two compounds engage mechanistically distinct receptor systems. The scientific rationale for studying the combination is that two mechanistically independent receptor systems are simultaneously active in the same neuroendocrine research model, enabling examination of receptor crosstalk, downstream signaling integration, and pathway interaction effects that neither compound can produce alone. Researchers studying Cagrilintide and Semaglutide blend use it alongside the individual standalone compounds to design comparative studies isolating single-pathway from dual-pathway experimental conditions.
Chemical Information
Cagrilintide Component:
- Chemical Name: Cagrilintide (AM833)
- Also Known As: AM833; long-acting amylin analog
- Compound Class: Dual amylin and calcitonin receptor agonist (DACRA); lipidated disulfide-bridged amylin analog
- Molecular Formula: C194H312N54O59S2
- Molecular Weight: approximately 4,409 Da
- CAS Number: 1415456-99-3
- Receptor Targets: Amylin receptors (AMY1, AMY2, AMY3); calcitonin receptor
Semaglutide Component:
- Chemical Name: Semaglutide
- Compound Class: GLP-1 receptor agonist; long-acting lipidated GLP-1 analog
- Molecular Formula: C187H291N45O59
- Molecular Weight: approximately 4,113 Da
- Receptor Target: GLP-1 receptor (GLP-1R; Gs-coupled Class B GPCR)
Blend:
- Ratio Option 1: Cagrilintide 5mg / Semaglutide 5mg
- Ratio Option 2: Cagrilintide 10mg / Semaglutide 10mg
- Production: Solid-phase peptide synthesis (SPPS) with lipidation modifications for both components
Applications
- Dual-pathway receptor activation research. The blend activates amylin receptor (DACRA) and GLP-1 receptor (GLP-1R) systems simultaneously; these receptor populations occupy distinct neuroanatomical locations (area postrema and nucleus tractus solitarius for amylin; hypothalamus and brainstem GLP-1R populations for semaglutide), enabling simultaneous dual-pathway input into the same neuroendocrine research model
- Receptor crosstalk and signaling integration studies. Amylin and GLP-1 receptor pathways share downstream neuroendocrine signaling territory despite activating through independent receptor systems; researchers use this blend to examine how dual-pathway activation produces signaling outcomes distinct from either compound studied alone
- Comparative single-pathway versus dual-pathway research designs. Cagrilintide and Semaglutide are available as standalone research compounds; the blend format enables the direct experimental comparison of dual-pathway versus single-pathway receptor activation in the same model system
- Neuroendocrine circuit research. Both receptor systems regulate overlapping but distinct hypothalamic and brainstem circuit activity; the blend is studied in neuroendocrine models where the interaction between amylin receptor and GLP-1 receptor downstream signaling is the primary research variable
- Pancreatic beta cell signaling research. Semaglutide component activates GLP-1R on pancreatic beta cells, driving glucose-dependent insulin secretion and glucagon suppression; amylin is co-secreted with insulin from beta cells; the blend enables study of both receptor systems in pancreatic endocrine cell models
Storage and Handling
Store lyophilized blend at -20C for long-term stability, or at 2-8C for short-term use. Protect from heat, moisture, and direct light. Both components are lipidated long-acting peptides; handle with care to avoid disrupting lipid modification integrity. Reconstitute immediately before use and avoid repeated freeze-thaw cycles to preserve compound integrity and receptor binding activity across experimental batches.
Compliance Notice
GLP-1 (C/S) is for laboratory research use only. It is not for human or veterinary use and carries no therapeutic, diagnostic, or clinical indication. This product has not been evaluated by the FDA. Cagrilintide and Semaglutide individually and in combination are under active clinical investigation by Novo Nordisk; the research-grade compounds in this blend are not equivalent to any clinical or pharmaceutical-grade formulation. By purchasing this product, the buyer confirms that they will follow appropriate institutional safety procedures and use it exclusively for controlled research.
